IMUX
Immunic (IMUX)
$
96About Immunic (IMUX)
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company was founded in May 2003 and is headquartered in New York, NY.
Details
Daily high
$1.00
Daily low
$0.95
Price at open
$1.00
52 Week High
$2.11
52 Week Low
$0.83
Market cap
95.4M
Dividend yield
0.00%
Volume
729,668
Avg. volume
1.4M
P/E ratio
-.96
Immunic News
Details
Daily high
$1.00
Daily low
$0.95
Price at open
$1.00
52 Week High
$2.11
52 Week Low
$0.83
Market cap
95.4M
Dividend yield
0.00%
Volume
729,668
Avg. volume
1.4M
P/E ratio
-.96